Does rituximab aggravate pre-existing hypogammaglobulinaemia?

Journal of Clinical Pathology

Volumn 63, Issue 3, 2010, Pages 275-277

  Diwakar, Lavanya ^a   Gorrie, Sheryl ^a   Richter, Alex ^a   Chapman, Oliver ^b   Dhillon, Paul ^b   Al Ghanmi, Fayza ^a   Noorani, Sadia ^a   Krishna, Mamidipudi T ^a   Huissoon, Aarnoud ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; HAEMOPHILUS VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PNEUMOCOCCUS POLYSACCHARIDE; RITUXIMAB; STEROID; TRANEXAMIC ACID; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; B LYMPHOCYTE; CASE REPORT; CELL FRACTIONATION; COMMON VARIABLE IMMUNODEFICIENCY; DRUG MEGADOSE; EAR INFECTION; FEMALE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; LOWER RESPIRATORY TRACT INFECTION; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MEDIASTINUM LYMPH NODE; MEMORY CELL; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SINUSITIS; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE;

EID: 77749255162     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.068940     Document Type: Article

References (10)

1. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-13.
2. Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002;73:100-4.
3. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies.Blood Rev 2002;16:61-4.
4. Tokunaga M, Fujii K, Saito K, et al. Downregulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005;44:176-82.
5. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5.
6. Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed onset neutropenia associated with rituximab therapy. Br J Haematol 2003;121:913-8.
7. Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1256-7.
8. van der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-9.
9. Nishio M, Endo T, Fujimoto K, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 2005;75:527-9.
10. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.